Ascendis Pharma A (ASND) Non-Current Deferred Tax Liability (2014 - 2025)

Ascendis Pharma A has disclosed Non-Current Deferred Tax Liability across 8 years of filings, most recently posting $11.2 million for Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $11.2 million, up 44.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.2 million (up 44.43% YoY), and the FY2025 annual result was $11.2 million, up 44.43% from the prior year.
• Non-Current Deferred Tax Liability came in at $11.2 million for Q4 2025 at Ascendis Pharma A, down from $12.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $12.0 million in Q3 2025 to a low of $6.3 million in Q4 2023.
• The 3-year median for Non-Current Deferred Tax Liability is $8.2 million (2024), against an average of $9.1 million.
• Peak annual rise in Non-Current Deferred Tax Liability reached 44.43% in 2025, while the deepest fall reached 5.68% in 2025.
• Ascendis Pharma A's Non-Current Deferred Tax Liability stood at $6.3 million in 2023, then climbed by 23.64% to $7.8 million in 2024, then soared by 44.43% to $11.2 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $11.2 million (Q4 2025), $12.0 million (Q3 2025), and $10.9 million (Q2 2025), per Business Quant data.